BackNeuronetics Overview

Neuronetics Profit Margin

Latest profit margin for Neuronetics: -24.48% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-31.32%
21.00% YoY

As of Mar 2026

Annual Profit Margin (TTM)

-24.48%
54.40% YoY

Trailing 12 months ending Mar 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Neuronetics (STIM) FAQ

Neuronetics (STIM) currently reports a profit margin of -24.48% as of March 2026. That compares with -53.67% in the prior-year period — up 54.4% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Neuronetics's profit margin history and peer comparisons.

Neuronetics's profit margin increased from -53.67% to -24.48% — a 54.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Neuronetics's profit margin of -24.48% is lower than the Healthcare sector average of 15.58%. That is roughly 257.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Neuronetics's current -24.48% should be judged against Healthcare norms (sector average: 15.58%) and against STIM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -24.48%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Neuronetics, and consider following STIM for alerts when major investors trade the stock.